Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Therapy for Wasting in Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 18 years~* Cystic fibrosis, diagnosed by either sweat chloride or genetic testing~* Less than 92% ideal body weight based on body mass index (BMI) of 22 for women and 23 for men~* Moderate or better pulmonary function (Forced Expiratory Volume (FEV1) \>40% of predicted).~* Agree to use an effective method of birth control to prevent pregnancy during the research study.~Women should not nurse (breast feed) a baby while on this study because Nutropin AQ may enter breast milk and possibly harm the child.~Exclusion Criteria:~* Pregnancy (positive pregnancy test) prior enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation or trial~* Pediatric patients~* Active neoplasm~* History of organ transplantation~* Prader Willi Syndrome who are severely obese or have severe respiratory impairment~* Patients with hepatic impairment resulting in abnormal coagulation studies (\>1.5 times normal reference range)~* Poorly controlled diabetes as determined by a Hemoglobin A1c greater than or equal to 9.0%.~* Individuals with electrocardiogram abnormality or cardiac pacing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone Therapy (Type: EXPERIMENTAL): Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).